Search | Clinical Trials Finder

Conditions: Copd
Interventions: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 2,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Salbutamol, LAMA; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 124,117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 10,355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 269
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more

Conditions: COPD
Interventions: Fluticasone Furoate-Vilanterol Trifenatate, Furoate-umeclidinium-vilanterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 120 Years
Enrollment: 17,281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo, GSK573179; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Phoenix, Arizona • San Diego, California • Upland, California + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719, Tiotropium, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 13
States / cities: Costa Mesa, California • Atlanta, Georgia • Duluth, Georgia + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Medford, Oregon • Greenville, South Carolina • Spartanburg, South Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 40 Years
Enrollment: 11,296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI, TIO/OLO, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 42
States / cities: Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol, Umeclidinium/ Vilanterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Hialeah, Florida • Baltimore, Maryland • St Louis, Missouri + 6 more

Conditions: Hyperhidrosis
Interventions: Umeclidinium, Vehicle; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 5
States / cities: Omaha, Nebraska • Raleigh, North Carolina • Austin, Texas + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hyperhidrosis
Interventions: Umeclidinium, Vehicle; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Raleigh, North Carolina • Austin, Texas

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI; Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125, GSK 573719 62.5, GW642444 25, Plb; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: QBW251, Placebo, COPD maintenance background therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Andalusia, Alabama • Los Angeles, California • Westminster, California + 22 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 11,316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more

Search by objective public record fields.

Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Replication of the IMPACT COPD Trial in Healthcare Claims Data

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

VENTURI (VENTilation Using Respiratory Imaging)

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)